NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Moderna, Inc. (MRNA) Stock Analysis

Moderna, Inc. (MRNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MRNA

$145.55

−$3.32 (−2.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MRNA with… →

MRNA Key Statistics

As of Sep 4, 2026
Trading
Open
$153.62
Previous Close
$148.87
Day's Range
141.52–154.69
52-Week Range
22.28–176.66
Volume
14.93M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.11
Valuation
Market Cap
$58.11B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
26.08
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.80
Financials (FY)
Revenue (FY)
$1.92B−39.92%
Net Income (FY)
−$2.82B
Profit marginThe share of revenue left as profit after all costs and taxes.
−141.43%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
399.24M
1-Year Return
+499.46%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
15.60M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MRNA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+393.56%
2025−29.08%
2024−58.19%
2023−44.63%
2022−29.28%
2021+143.11%
2020+434.10%
2019+28.09%
2018 (partial year)−17.90%

As of September 4, 2026.

MRNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.92B−$2.82B−146.8%
2024$3.20B−$3.56B−111.3%
2023$6.75B−$4.71B−69.8%
2022$18.88B$8.36B44.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.92B$1.05B−$3.07B−$2.82B−146.8%
2024$3.20B$1.74B−$3.95B−$3.56B−111.3%
2023$6.75B$2.06B−$4.24B−$4.71B−69.8%
2022$18.88B$13.46B$9.42B$8.36B44.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MRNA Valuation vs Biotechnology Median

Median of 656 stocks
MetricMRNABiotechnology medianvs median
P/S ratio26.0815.2671% above
Profit margin−141.43%0.00%141.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Moderna, Inc. (MRNA) carries a market capitalisation of $58.11B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 4,700 employees.

The most recent close on file for MRNA is $145.55, dated September 4, 2026. That is −$3.32 (−2.23%) against the previous close. Over the past 52 weeks the price has ranged from $22.28 to $176.66. The latest close sits 553.28% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.92B. That is −39.92% against the prior fiscal year, when revenue was $3.20B. The same year closed with a net loss of $2.82B. Profit margin runs at −141.43%. That is 141.4 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −7.8.

Across the 4 fiscal years on file, revenue moves from $18.88B in 2022 to $1.92B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 26.08 times revenue. On price-to-sales that is 70.87% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.11. Daily returns over the trailing 7 years annualize to a volatility of 99.37%. Over the trailing twelve months the price has returned +499.46%. Measured over 5 years, that is −18.97% a year compounded.

Growth & Income

No dividend is on file for MRNA.

So far in 2026 the price is +393.56%. Across the complete calendar years on file, 2020 returned +434.10% and 2024 returned −58.19%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Moderna, Inc. (MRNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Moderna, Inc. MRNA $58.11B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Moderna, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B

 RPRX

Royalty Pharma plc

$36.96B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Visit website →